Integrated Environmental Technologies, Ltd. Announces MRSA - Specific EPA Registration Of EcaFlo(R) Excelyte(R)

Main Category: MRSA / Drug Resistance
Also Included In: Infectious Diseases / Bacteria / Viruses
Article Date: 29 Apr 2009 - 7:00 PDT

email icon email to a friend   printer icon printer friendly   write icon opinions  

Current Article Ratings:

Patient / Public:not yet rated

Healthcare Prof:3 stars

3 (1 votes)


Integrated Environmental Technologies, Ltd. (OTCBB: IEVM) and Benchmark Research & Technology (BRT) announced that the U.S. EPA has approved EcaFlo® Anolyte (trademarked Excelyte®), as a registered and effective biocide against MRSA (Methicillin-Resistant Staphylococcus Aureus), one of the most prolific and feared bacterial infections facing the public today. Today's announcement comes only a few months after the EPA approved EcaFlo® Excelyte® as a high-level disinfectant/biocide.

Since gaining EPA registration, Excelyte® has quickly gained momentum and is fast becoming the microbiocide of choice for hospitals, universities, public school systems, medical and veterinary schools , cleaning services, food processing, athletic departments, veterinary clinics, medical research labs, state, county, city and federal governments and professional sports teams. Excelyte® is the choice for these entities because MRSA and other bacterial threats are more than just a hospital problem. Excelyte® is a non-toxic, and yet exceptionally strong, oxidizing solution that destroys MRSA, E. coli, Salmonella, Hepatitis C, TB and almost every other pathogen in a manner that prevents them from mutating and thereby preventing the development of new resistant microorganisms.

South Carolina-based IET specializes in the manufacturing and production of the EcaFlo® system, the only system in the U.S. producing an EPA registered anolyte solution (Excelyte®). William E. Prince, President and CEO of IET said, "The U.S. Environmental Protection Agency has considered the MRSA-specific research results we submitted, and has determined it is indeed effective in destroying MRSA. We believe that EcaFlo® Excelyte® is the most effective biocide in the world today. IET is committed to working with its clients and partners to further inform the public on the multitude of applications for the product. We believe Excelyte® revolutionizes the way we currently disinfect to prevent the spread of MRSA and other bugs."

Due to the non-toxic nature of Excelyte® and proven research supporting its efficacy against MRSA and other bacteria, University General Hospital in Houston, Texas announced that it would be the first hospital in the country to implement Excelyte® as its disinfecting agent. Excelyte® was donated to help in the disaster clean-up and restoration efforts following Hurricane Ike and many school systems and county governments in the Carolinas are making the change to Excelyte®.

Source
Benchmark Research & Technology

Article adapted by Medical News Today from original press release.
Visit our mrsa / drug resistance section for the latest news on this subject.
There are no references listed for this article.
Please use one of the following formats to cite this article in your essay, paper or report:

MLA
Benchmark Research & Technology. "Integrated Environmental Technologies, Ltd. Announces MRSA - Specific EPA Registration Of EcaFlo(R) Excelyte(R)." Medical News Today. MediLexicon, Intl., 29 Apr. 2009. Web.
13 Feb. 2012. <http://www.medicalnewstoday.com/releases/148145.php>

APA
Benchmark Research & Technology. (2009, April 29). "Integrated Environmental Technologies, Ltd. Announces MRSA - Specific EPA Registration Of EcaFlo(R) Excelyte(R)." Medical News Today. Retrieved from
http://www.medicalnewstoday.com/releases/148145.php.

Please note: If no author information is provided, the source is cited instead.


MRSA / Drug Resistance

Most Popular Articles



Follow Our MRSA News On Twitter

Follow Us On Twitter
Get the latest news for this category delivered straight to your Twitter account. Simply visit our MRSA / Drug Resistance Twitter account and select the 'follow' option.



View list of all 'What Is...' articles »